Ali Tehrani
Net Worth

Last updated:

What is Ali Tehrani net worth?

The estimated net worth of Dr. Ali Tehrani is at least $9,176,438 as of 16 Jul 2021. He owns shares worth $3,670,583 as insider, has earned $239,895 from insider trading and has received compensation worth at least $5,265,960 in Zymeworks Inc..

What is the salary of Ali Tehrani?

Dr. Ali Tehrani salary is $877,660 per year as Co-Founder, Pres, Chief Executive Officer & Director in Zymeworks Inc..

How old is Ali Tehrani?

Dr. Ali Tehrani is 53 years old, born in 1972.

What stocks does Ali Tehrani currently own?

As insider, Dr. Ali Tehrani owns shares in one company:

Company Title Shares Price per share Total value
Zymeworks Inc. (ZYME) Co-Founder, Pres, Chief Executive Officer & Director 260,325 $14.1 $3,670,583

What does Zymeworks Inc. do?

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.

ZYME logo
ZYME
Zymeworks Inc.
$14.1

Ali Tehrani insider trading

Zymeworks Inc.

Dr. Ali Tehrani has made 7 insider trades between 2019-2021, according to the Form 4 filled with the SEC. Most recently he sold 41,191 units of ZYME stock on 16 Jul 2021.

The largest trade he's ever made was exercising 41,191 units of ZYME stock on 16 Jul 2021. As of 16 Jul 2021 he still owns at least 260,325 units of ZYME stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Shares 41,191 N/A N/A
Option
Common Shares 41,191 N/A N/A
Option
Stock Option (Right to Buy) 41,191 N/A N/A
Option
Common Shares 3,800 N/A N/A
Option
Stock Option (Right to Buy) 3,800 N/A N/A
Sale
Common Shares 3,800 N/A N/A
Option
Stock Option (Right to Buy) 12,669 $4.31 $54,553
Option
Common Shares 12,669 $4.31 $54,553
Sale
Common Shares 12,669 $4.31 $54,553
Sale
Common Shares 4,392 N/A N/A
Option
Restricted Stock Unit 7,708 N/A N/A
Option
Common Shares 7,708 N/A N/A
Sale
Common Shares 850 N/A N/A
Sale
Common Shares 3,500 $39.04 $136,623
Option
Common Shares 1,000 N/A N/A
Option
Stock Option (Right to Buy) 1,000 N/A N/A
Purchase
Common Shares 575 $33.39 $19,199
Sale
Common Shares 3,000 $16.24 $48,720

Zymeworks key executives

Zymeworks Inc. executives and other stock owners filed with the SEC:

  • Dr. Ali Tehrani (53) Co-Founder, Pres, Chief Executive Officer & Director
  • Dr. Anthony J. Polverino Ph.D. (62) Chief Scientific Officer & Executive Vice President of Early Devel.
  • Mr. Neil A. Klompas C.A., CPA, CPA, CA (53) Executive Vice President of Bus. Operations & Chief Financial Officer
  • Ms. Kathryn O'Driscoll (61) Chief People Officer